All funds
hikma-ventures logo

hikma-ventures

$4.3Tdisclosed portfolio round capital
10 Oct, 2018last investment
1portfolio companies
12team members

Analyst signals

Portfolio activity and matriculation

Metrics use all recorded activity through 21 Jul 2026 across series a. Later-round outcomes are capped at the period end.

100%companies with a later round · 1/1
1000000.00×median round-size step-up · n=1
Not availablemedian valuation step-up · n=0
0%recorded-solo rate · 0 solo / 2 syndicated
Healthcare · 1 companies

These are activity signals, not fund-return metrics. Round capital is the full disclosed financing amount, not this fund's check size. “Recorded solo” means only one investor is present in the source data and is a lead signal, not verified lead status; syndicated rounds are a co-investor or follower signal. IRR, TVPI, DPI, ownership, exits, and market beta cannot be calculated from the available records.

People

Team

A

Ali Al-Husry

Non-Executive Director

B

Bassam Kanaan

EVP, Corporate Development and M&A

C

Cynthia Flowers

Independent Non-Executive Director

D

Deneen Vojta

Independent Non-Executive Director

D

Dr. Laith Khoury

Advisor

D

Dr. Ramy Abou Ghayda

Advisor

H

Haya Khoury

Analyst

L

Lana Ghanem

Managing Director

M

Mazen Darwazah

Executive Vice Chairman, President of MENA

O

Omar Sati

Advisor

R

Richard Girling

Advisor

S

Salma Al-Zu'bi

Principal

Portfolio

Investments

Full financing histories for portfolio companies. Highlighted rounds are those where hikma-ventures is recorded as an investor.

Nebula Genomics logo

Nebula Genomics

out of scope
Healthcare

Nebula Genomics is a personal genomics company that provides advanced DNA testing through 30x Whole Genome Sequencing, decoding 100% of a user's DNA. Founded by Harvard and MIT Professor George Church, the company analyzes saliva samples to offer insights into health, ancestry, and genetic traits. Nebula Genomics prioritizes user privacy and control over their data, while also offering opportunities to participate in scientific research. Their services, which are intended for research, informational, and educational use, are also available through DNA Complete.

Series A10 Oct, 2018$4.3T roundSyndicated · 12 disclosed investors
Series A1 Aug, 2018$4.3M roundSyndicated · 10 disclosed investors